India’s Roselabs Invests $67M in New Pre-Filled Syringe Facility

By Zachary Brennan

- Last updated on GMT

India’s Roselabs Invests $67M in New Pre-Filled Syringe Facility

Related tags International trade

Roselabs Bioscience has invested $67M into a pre-filled syringe facility in India and is exploring the option of exporting the products to 35 countries in unregulated markets in southeast Asia, Latin America and Africa.

We are currently producing [800,000] syringes per day and it is only operating at half of the installed capacity​,” Karan Gandhi, a spokesman for Roselabs told “Gradually as the export market grows, we believe we would be able to work on full capacity​.”

The site, which is currently operating at about 50% capacity, according to Gandhi, earned WHO-GMP (World Health Organization – good manufacturing practices) certification in May after beginning commercial production in January. He added the company is in the process of obtaining CE and ISO certification as well.

We are already present in the domestic [Indian] market with a range of 26 molecules all in PFS [pre-filled syringes]​,” Gandhi said.

The facility is the first in India to commercialise eight lanes of PFS filling with dedicated individual in therapeutic segments including peptide, recombinant, hormones, biotech, ophthalmic and others, along with manufacturing of complete empty devices.

With the capability to make both glass and polymer syringes, Roselabs will focus on making empty glass and polymer syringes, contract manufacturing, development of any formulation in PFS, development of customised drug delivery system and marketing formulations under its own brand name.

Zameer Agarwal, Director of Roselabs Bioscience noted, “The existing and potential market for pre-filled syringes in India and globally is huge. Nearly 95% of PFS are imported into India which is one of the fastest growing markets for this sector​.”

Related news

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more